Abstract | BACKGROUND: METHODS: RESULTS: Considering all subjects enrolled in the eleven RCTs as a whole to investigate the occurrence of AEs, we extrapolated an events/subjects rate of 57.8% for AEs (6,445/11,144), 7.7% for serious AEs (975/12,647), 9.1% for bleeding events (1,229/13,454), and 3.2% for discontinuation of apixaban (421/13,039). The percentage of AEs was lower in subjects treated with apixaban than in those treated with conventional VTE therapy (53% vs 56.3%, respectively). However, only one study provided data on separate analysis by sex of either efficacy or safety of apixaban. CONCLUSION: Under the patient's perspective, apixaban could represent a good choice in the treatment of VTE, due to its pharmacological, economical, and safety profile. These positive aspects are certainly present in both sexes, since the available studies include a correct percentage of women, but data with separate analyses by sex are extremely limited. Future clinical trials should include in their results on clinical impact and outcomes a stratification by sex, and studies aimed to evaluate possible sex-related differences for these drugs should be strongly encouraged.
|
Authors | Fabio Fabbian, Alfredo De Giorgi, Ruana Tiseo, Beatrice Zucchi, Roberto Manfredini |
Journal | Patient preference and adherence
(Patient Prefer Adherence)
Vol. 10
Pg. 73-80
( 2016)
ISSN: 1177-889X [Print] New Zealand |
PMID | 26869771
(Publication Type: Journal Article, Review)
|